Antithyroid drugs are used to treat methimazole mechanism of action m, initially to control the symptoms of thyrotoxicosis. They can be used as monotherapy (thiamine, such as methimazole, is often used in this way) or in euthyroid patients prior to thyroidectomy or radioactive iodine therapy. Graves' disease exhibits spontaneous remission, and some have suggested prolonging remission by using high-dose thioamides in combination with thyroxine, but evidence for this is scant. Because of the way they work, thioureas take 1-2 months to control symptoms. Preoperative euthyroidism can be achieved with sulfonamides, iodides, iodides, or a combination of sulfonamides and iodides (or iodides). Potassium perchlorate, although not routinely used to treat hyperthyroidism due to toxicity with long-term use, has been repurposed for short-term treatment of amiodarone-induced hyperthyroidism. Amiodarone-induced thyrotoxicosis occurs in 2-12% of patients receiving this drug due to iodine-induced hypersynthesis of thyroid hormones in patients with nodular goiter or latent Graves disease or amiodarone or iodine thyroid-damaging processes . Perchlorate is often used in combination with thiamines, and potassium perchlorate therapy is discontinued after 30-40 days Wolff (1998). Potassium perchlorate is also used in combination with radioactive iodine to detect thyroid organic iodine deficiency, the so-called "perchlorate discharge test" Wolff

The activity of all microsomal CYPs can be inhibited with NADPH CYP reductase antibodies, CYP selective chemical inhibitors (e.g. 1-aminobenzotriazole), carbon monoxide, or addition of detergents. Antibodies against FMO are generally weak inhibitors, and the only chemical inhibitor against FMO is methimazole [26, 27]. FMO activity is not affected by non-ionic detergents or carbon monoxide, however, most FMOs are readily inhibited by brief incubation (2 min) at 45–50°C in the absence of NADPH. To estimate the relative contribution of FMOs to CYPs, the standard approach is to use a combination of these methods, for example, pre-incubation at high temperature and incubation with and without the FMO inhibitor methimazole. With regard to distinguishing between FMO and CYP-mediated metabolism, the inhibition results for methimazole should be interpreted with caution, as methimazole may be a substrate for CYPs